|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-5.27/-0.32
|
企业价值
3.74B
|
资产负债 |
每股账面净值
4.02
|
现金流量 |
现金流量率
--
|
损益表 |
收益
270.60M
|
每股收益
4.70
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/02 23:26 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |